LVZPF: AI 评分 49/100 — AI 分析 (4月 2026)

Livzon Pharmaceutical Group Inc. is a Chinese pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products and active pharmaceutical ingredients (APIs) both domestically and internationally. The company's diverse portfolio includes products for assisted reproduction, gastrointestinal health, psychiatric and neurological conditions, and traditional Chinese medicine.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Livzon Pharmaceutical Group Inc., based in China, develops, manufactures, and markets a diverse range of pharmaceutical products, including APIs, diagnostic reagents, and traditional Chinese medicines, targeting key therapeutic areas such as assisted reproduction, gastrointestinal health, and psychiatric disorders, with a growing international presence.

LVZPF是做什么的？

Livzon Pharmaceutical Group Inc., established in 1985 and headquartered in Zhuhai, China, is a comprehensive pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products, active pharmaceutical ingredients (APIs), and intermediates. The company's origins lie in the growing Chinese pharmaceutical market, where it initially focused on developing and manufacturing essential medicines. Over the years, Livzon has expanded its product portfolio to include a wide array of therapeutic areas, including assisted reproduction, gastrointestinal health, psychiatric and neurological conditions, and traditional Chinese medicine. Livzon's key products include leuprorelin acetate microspheres, urofollitropin, and menotropins for injection, which are used in the assisted reproduction field. For gastrointestinal health, it offers Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products. In the psychiatric and neurological field, Livzon provides fluvoxamine maleate and perospirone hydrochloride tablets. The company also produces traditional Chinese medicine products such as shenqi fuzheng injection and anti-viral granules. Furthermore, Livzon manufactures APIs and intermediates, including mevastatin, acarbose, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium. The company also offers a range of diagnostic reagents, including diagnostic kits for IgM antibody to mycoplasma pneumonia, human immunodeficiency virus antibody, and antinuclear antibody test kits. Livzon's geographic reach extends beyond China, with exports to international markets.

LVZPF的投资论点是什么？

Livzon Pharmaceutical Group Inc. presents a notable market position due to its diversified product portfolio, strong presence in the Chinese pharmaceutical market, and expanding international reach. The company's focus on key therapeutic areas such as assisted reproduction and gastrointestinal health positions it well to capitalize on growing demand for these treatments. With a profit margin of 18.1% and an ROE of 16.4%, Livzon demonstrates strong profitability and efficient capital utilization. The company's low beta of 0.39 suggests relatively low volatility compared to the overall market. Upcoming catalysts include potential regulatory approvals for new products and expansion into new geographic markets. However, investors should be aware of potential risks such as regulatory changes in China and increased competition from other pharmaceutical companies.

LVZPF在哪个行业运营？

Livzon Pharmaceutical Group Inc. operates in the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. The Chinese pharmaceutical market, in particular, is experiencing significant growth due to increasing healthcare expenditure and an aging population. Livzon competes with both domestic and international pharmaceutical companies, including generic drug manufacturers and innovative drug developers. The company's focus on specialty and generic drugs, as well as traditional Chinese medicine, allows it to cater to a broad range of patient needs. The global pharmaceuticals market is projected to reach $1.7 trillion by 2028, growing at a CAGR of 5%.

Drug Manufacturers - Specialty & Generic

Healthcare

LVZPF有哪些增长机遇？

Expansion in the Assisted Reproduction Market: The global assisted reproductive technology (ART) market is projected to reach $45 billion by 2030, driven by increasing infertility rates and rising awareness of ART procedures. Livzon's existing portfolio of fertility drugs, including leuprorelin acetate microspheres, urofollitropin, and menotropins, positions it well to capture a larger share of this growing market. Strategic partnerships with fertility clinics and increased marketing efforts could further enhance Livzon's market penetration.
Growth in the Gastrointestinal Drug Market: The global gastrointestinal drugs market is expected to reach $55 billion by 2027, fueled by the rising prevalence of gastrointestinal disorders such as acid reflux, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD). Livzon's Ilaprazole enteric-coated tablets and bismuth potassium citrate products address these conditions, providing a solid foundation for growth in this market. Further research and development of innovative gastrointestinal therapies could create additional growth opportunities.
Increased Focus on Traditional Chinese Medicine (TCM): The global market for traditional medicine is experiencing a resurgence, driven by increasing consumer interest in natural and holistic healthcare solutions. Livzon's shenqi fuzheng injection and anti-viral granules cater to this demand, offering a unique value proposition in the market. Investing in research to validate the efficacy of TCM products and expanding distribution channels could unlock significant growth potential.
Expansion into International Markets: While Livzon already exports its products internationally, there is significant potential to further expand its geographic reach. Targeting emerging markets with growing healthcare expenditure and unmet medical needs could drive substantial revenue growth. Establishing strategic partnerships with local distributors and adapting products to meet local regulatory requirements are crucial for successful international expansion.
Development of Novel Diagnostic Reagents: The global diagnostics market is experiencing rapid growth, driven by technological advancements and increasing demand for early and accurate disease detection. Livzon's existing portfolio of diagnostic reagents, including kits for detecting infectious diseases and autoimmune disorders, provides a strong foundation for growth in this market. Investing in research and development to create novel diagnostic tools and expanding distribution networks could drive significant revenue growth.

Market capitalization of $4.63 billion reflects Livzon's significant presence in the pharmaceutical industry.
Profit margin of 18.1% indicates strong profitability and efficient cost management.
Gross margin of 64.5% demonstrates the company's ability to generate revenue from its products and services.
Return on Equity (ROE) of 16.4% signifies effective utilization of shareholder equity to generate profits.
Debt-to-equity ratio of 25.49 indicates a moderate level of financial leverage.

LVZPF提供哪些产品和服务？

Researches and develops pharmaceutical products.
Produces a range of pharmaceutical products, including drugs and APIs.
Exports pharmaceutical products to international markets.
Sells pharmaceutical products in the People's Republic of China.
Manufactures active pharmaceutical ingredients (APIs) and intermediates.
Offers diagnostic reagents and kits for various diseases.

LVZPF如何赚钱？

Develops and manufactures pharmaceutical products, APIs, and diagnostic reagents.
Sells products through distributors and directly to healthcare providers.
Generates revenue from both domestic and international sales.
Invests in research and development to create new products and improve existing ones.

Hospitals and clinics
Pharmacies and drug stores
Healthcare providers
Patients

Diversified product portfolio across multiple therapeutic areas.
Strong presence in the Chinese pharmaceutical market.
Established manufacturing capabilities for APIs and pharmaceutical products.
Research and development capabilities for creating new products.
Established distribution network in China and internationally.

什么因素可能推动LVZPF股价上涨？

Upcoming: Potential regulatory approvals for new pharmaceutical products in China.
Upcoming: Expansion into new international markets, particularly in Southeast Asia.
Ongoing: Increasing demand for assisted reproductive technology (ART) services in China.
Ongoing: Growing prevalence of gastrointestinal disorders driving demand for related treatments.

LVZPF的主要风险是什么？

Potential: Changes in Chinese pharmaceutical regulations could impact profitability.
Potential: Increased competition from domestic and international pharmaceutical companies.
Potential: Intellectual property infringement could erode market share.
Ongoing: Fluctuations in currency exchange rates could affect international sales.
Ongoing: Dependence on key suppliers for APIs and raw materials.

LVZPF的核心优势是什么？

Diversified product portfolio.
Strong presence in the Chinese market.
Established manufacturing capabilities.
Research and development capabilities.

LVZPF的劣势是什么？

Reliance on the Chinese market.
Exposure to regulatory changes in China.
Limited brand recognition in international markets.
Dependence on third-party distributors.

LVZPF有哪些机遇？

Expansion into new therapeutic areas.
Growth in emerging markets.
Development of novel diagnostic tools.
Strategic partnerships and acquisitions.

LVZPF面临哪些威胁？

Increased competition from other pharmaceutical companies.
Stringent regulatory requirements.
Price pressures from generic drugs.
Intellectual property infringement.

LVZPF的竞争对手是谁？

Hubei Biocause Pharmaceutical Co Ltd — Focus on antibiotic products. — (SHSE:600276)
Huabang Life Science Co Ltd — Diversified pharmaceutical products. — (SZSE:000999)
Lunan Pharmaceutical Group Corp Ltd — Focus on generic drugs and APIs. — (SSE:600513)

Key Metrics

MoonshotScore: 49/100

Company Profile

Headquarters: Zhuhai, China
Employees: 9,067

AI Insight

AI analysis pending for LVZPF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Livzon Pharmaceutical Group Inc. do?

Livzon Pharmaceutical Group Inc. is a Chinese pharmaceutical company that researches, develops, produces, and sells pharmaceutical products, active pharmaceutical ingredients (APIs), and intermediates. The company's product portfolio includes drugs for assisted reproduction, gastrointestinal health, psychiatric and neurological conditions, and traditional Chinese medicine. Livzon operates both domestically and internationally, serving hospitals, clinics, pharmacies, and healthcare providers. The company also manufactures diagnostic reagents and kits for various diseases.

What do analysts say about LVZPF stock?

AI analysis is pending for LVZPF. Therefore, analyst consensus, valuation metrics, and growth considerations are currently unavailable. Investors should conduct their own due diligence and consult with financial professionals before making any investment decisions. Further information will be available once the AI analysis is complete. Please check back for updates.

What are the main risks for LVZPF?

Livzon Pharmaceutical Group Inc. faces several risks, including regulatory changes in China's pharmaceutical industry, increased competition from domestic and international companies, and potential intellectual property infringement. The company is also exposed to currency exchange rate fluctuations and dependence on key suppliers for APIs and raw materials. Investors should carefully consider these risks before investing in LVZPF.